J. Luzum

发表

The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.

Gerald A. Higgins, B. Athey, Ari Allyn-Feuer, 2018, Pharmacogenomics.

Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy.

J. Rae, J. Luzum, Hao-Jie Zhu, 2017, Pharmacogenomics.

Moving Pharmacogenetics Into Practice: It’s All About the Evidence!

S. V. Van Driest, L. Cavallari, J. Luzum, 2021, Clinical pharmacology and therapeutics.

Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure

W. Kraus, C. O'connor, K. Adams, 2020, Circulation. Heart failure.

Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort.

M. Christman, J. Luzum, K. Sweet, 2017, Personalized medicine.

Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

J. Luzum, Jason C Cheung, Jasmine A. Luzum, 2018, Pharmacogenomics.

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms

L. Gong, T. Klein, D. Voora, 2022, Clinical pharmacology and therapeutics.

Genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants.

J. Luzum, C. A. A. Chahal, A. I. Lopez-Medina, 2022, Pharmacogenomics.

Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms

H. Ochs-Balcom, J. Luzum, G. Vladutiu, 2020, Pharmacogenetics and genomics.

BNP and Precision Medicine

J. Luzum, D. Lanfear, Jasmine A. Luzum, 2021, JACC. Basic to translational science.

Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association

E. Ashley, C. Willer, Christopher J O'Donnell, 2022, Circulation.

Coenzyme Q10 supplementation for the treatment of statin-associated muscle symptoms.

H. Ochs-Balcom, J. Luzum, G. Vladutiu, 2022, Future cardiology.

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

Yee Ming Lee, K. Sangkuhl, T. Klein, 2022, Clinical pharmacology and therapeutics.

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

R. Krauss, D. Baldassarre, M. Medina, 2014, Pharmacogenetics and genomics.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems

R. Altman, M. Relling, M. Whirl‐Carrillo, 2017, Clinical pharmacology and therapeutics.

Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma.

M. Phelps, J. Luzum, Jiang Wang, 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

N. Limdi, J. Luzum, Hao-Jie Zhu, 2022, Frontiers in Pharmacology.